The Strategic Dialogue on Tobacco Harm Reduction: a vision and blueprint for action in the US

被引:175
作者
Zeller, Mitchell [1 ]
Hatsukami, Dorothy [1 ]
机构
[1] Pinney Associates, Bethesda, MD 20814 USA
关键词
CLINICAL-EXPOSURE EVALUATION; CIGARETTE-SMOKING; PUBLIC-HEALTH; CARDIOVASCULAR-DISEASE; CARCINOGEN EXPOSURE; NICOTINE; SMOKERS; PRODUCTS; NITROSAMINES; ADDICTION;
D O I
10.1136/tc.2008.027318
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
The issues related to tobacco harm reduction continue to challenge the tobacco control research and policy communities. The potential for combusting tobacco products to reduce exposure and risk remains largely unknown, but this has not stopped manufacturers from offering such products making these claims. The role of oral tobacco products in a harm reduction regimen has also been a source of dialogue and debate. Within the last few years, major cigarette manufacturing companies have begun selling smokeless products for the first time, claiming to target current cigarette smokers. Other cigarette manufacturers are also offering smokeless products in markets around the world. The harm reduction debate has at times been divisive. There has been no unifying set of principles or goals articulated to guide tobacco control efforts. In particular, the research needs are extraordinarily high in order to drive evidence-based policy in this area and avoid the mistakes made with "light'' cigarettes. This paper discusses recommendations from a strategic dialogue held with key, mostly US-based tobacco control researchers and policy makers to develop a strategic vision and blueprint for research, policy and communications to reduce the harm from tobacco for the US. Short-term and long-term objectives are described.
引用
收藏
页码:324 / 332
页数:9
相关论文
共 70 条
[1]   Chronic disease mortality in a cohort of smokeless tobacco users [J].
Accortt, NA ;
Waterbor, JW ;
Beall, C ;
Howard, G .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2002, 156 (08) :730-737
[2]  
[Anonymous], 1988, HLTH CONS SMOK NIC A
[3]   Tobacco-specific nitrosamines in tobacco from US brand and non-US brand cigarettes [J].
Ashley, DL ;
Beeson, MD ;
Johnson, DR ;
McCraw, JM ;
Richter, P ;
Pirkle, JL ;
Pechacek, TF ;
Song, SQ ;
Watson, CH .
NICOTINE & TOBACCO RESEARCH, 2003, 5 (03) :323-331
[4]   Stop-smoking medications: Who uses them, who misuses them, and who is misinformed about them? [J].
Bansal, MA ;
Cummings, KM ;
Hyland, A ;
Giovino, GA .
NICOTINE & TOBACCO RESEARCH, 2004, 6 :303-310
[5]   Nicotine and carcinogen exposure with smoking of progressively reduced nicotine content cigarette [J].
Benowitz, Neal L. ;
Hall, Sharon M. ;
Stewart, Susan ;
Wilson, Margaret ;
Dempsey, Delia ;
Jacob, Peyton, III .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2007, 16 (11) :2479-2485
[6]   Nicotine intake and dose response when smoking reduced-nicotine content cigarettes [J].
Benowitz, Neal L. ;
Jacob, Peyton, III ;
Herrera, Brenda .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (06) :703-714
[7]   Cigarette smoking and cardiovascular disease: Pathophysiology and implications for treatment [J].
Benowitz, NL .
PROGRESS IN CARDIOVASCULAR DISEASES, 2003, 46 (01) :91-111
[8]   ESTABLISHING A NICOTINE THRESHOLD FOR ADDICTION - THE IMPLICATIONS FOR TOBACCO REGULATION [J].
BENOWITZ, NL ;
HENNINGFIELD, JE .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (02) :123-125
[9]  
Benowitz NL, 1999, J AM COLL CARDIOL, V34, P1791
[10]  
[Bonnie R.J. Institute of Medicine Institute of Medicine], 2007, ENDING TOBACCO PROBL